Free Trial

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
$0.73
+0.01 (+1.38%)
(As of 10/31/2024 ET)

VRPX vs. LGVN, PMCB, NRXP, INAB, INDP, CLDI, ALZN, WENA, AYTU, and TSBX

Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Longeveron (LGVN), PharmaCyte Biotech (PMCB), NRx Pharmaceuticals (NRXP), IN8bio (INAB), Indaptus Therapeutics (INDP), Calidi Biotherapeutics (CLDI), Alzamend Neuro (ALZN), ANEW Medical (WENA), Aytu BioPharma (AYTU), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry.

Virpax Pharmaceuticals vs.

Virpax Pharmaceuticals (NASDAQ:VRPX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.

In the previous week, Longeveron had 4 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for Virpax Pharmaceuticals. Longeveron's average media sentiment score of 0.73 beat Virpax Pharmaceuticals' score of 0.44 indicating that Longeveron is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Longeveron Positive

Virpax Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,513.83%. Longeveron's return on equity of -237.57% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -242.73%
Longeveron -1,513.83%-237.57%-140.97%

Longeveron received 9 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 92.31% of users gave Longeveron an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Virpax PharmaceuticalsOutperform Votes
3
60.00%
Underperform Votes
2
40.00%
LongeveronOutperform Votes
12
92.31%
Underperform Votes
1
7.69%

Virpax Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Virpax Pharmaceuticals presently has a consensus target price of $3.00, suggesting a potential upside of 317.25%. Longeveron has a consensus target price of $8.00, suggesting a potential upside of 270.37%. Given Virpax Pharmaceuticals' higher possible upside, equities research analysts plainly believe Virpax Pharmaceuticals is more favorable than Longeveron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Longeveron
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.2% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 19.1% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virpax Pharmaceuticals has higher earnings, but lower revenue than Longeveron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A
Longeveron$1.23M25.24-$21.41M-$8.74-0.25

Summary

Longeveron beats Virpax Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

MetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.51M$7.20B$5.41B$8.61B
Dividend YieldN/A8.77%5.22%4.20%
P/E RatioN/A16.37141.1017.75
Price / SalesN/A363.711,532.1394.15
Price / CashN/A50.1638.9333.56
Price / Book0.445.744.784.64
Net Income-$15.19M$151.16M$115.44M$225.71M
7 Day Performance15.95%-0.10%0.33%0.66%
1 Month Performance3.54%7.86%4.83%2.80%
1 Year Performance-89.95%40.54%39.74%34.26%

Virpax Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
1.7095 of 5 stars
$0.73
+1.4%
$3.00
+309.3%
-90.0%$3.58MN/A0.007
LGVN
Longeveron
3.0998 of 5 stars
$2.18
-1.4%
$8.00
+267.0%
-88.8%$13.84M$1.23M-0.2520Short Interest ↓
PMCB
PharmaCyte Biotech
1.466 of 5 stars
$1.80
flat
N/A-10.5%$13.82MN/A2.732Gap Down
NRXP
NRx Pharmaceuticals
2.1749 of 5 stars
$1.29
+6.6%
$31.50
+2,341.9%
-95.7%$13.80MN/A-0.482Gap Up
INAB
IN8bio
4.0575 of 5 stars
$0.30
-3.2%
$10.00
+3,223.4%
-71.5%$13.28MN/A-0.3620Short Interest ↓
Positive News
INDP
Indaptus Therapeutics
3.9325 of 5 stars
$1.54
+14.1%
$12.00
+679.2%
-42.6%$13.15MN/A-0.836Upcoming Earnings
Short Interest ↓
Gap Down
CLDI
Calidi Biotherapeutics
2.3358 of 5 stars
$1.18
+8.3%
$16.67
+1,312.4%
N/A$13.11M$50,000.000.0041Gap Down
High Trading Volume
ALZN
Alzamend Neuro
0.7254 of 5 stars
$1.63
+1.2%
N/A-92.0%$13.01MN/A-1.654Gap Up
WENA
ANEW Medical
N/A$0.73
-0.5%
N/AN/A$12.51MN/A0.00N/AGap Up
AYTU
Aytu BioPharma
1.2314 of 5 stars
$2.08
-3.7%
N/A-25.5%$12.44M$81.00M-0.73160Short Interest ↓
Positive News
TSBX
Turnstone Biologics
3.8085 of 5 stars
$0.54
+3.9%
$2.13
+297.2%
-80.8%$12.38M$19.31M-0.1582Positive News

Related Companies and Tools


This page (NASDAQ:VRPX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners